Eli Lilly will cut prices for some older insulins later this year and immediately expand a cap on costs insured patients pay to fill prescriptions. Lilly said it will cut the list price for its ...

Indianapolis-based drugmaker Eli Lilly and Company has announced price reductions of 70% for its most commonly prescribed insulins, as well as expansion of its Insulin Value Program, capping ...

Eli Lilly is looking to approach regulators for approval of its once-weekly insulin for type 2 diabetes (T2D) after it proved non-inferior to daily dosing.

Eli Lilly's Tirzepatide Continues To Win the Battle of the Bulge Lilly's blockbuster Tirzepatide continues to edge out Novo Nordisk's Semaglutide drugs Ozempic and Wegovy when measuring weight ...

Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. surprised health and privacy experts when he announced June 24 that his agency would launch a massive advertising campaign to encourage ...

Eli Lilly and Company (NYSE:LLY) is one of the 10 Best Non-Tech Stocks to Buy and Hold For 3 Years. On June 22, Eli Lilly and ...

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

The benefit-risk balance is tipping more in favor of Eli Lilly’s Kisunla in early Alzheimer’s disease as the FDA ...

Lilly's Kisunla gets FDA approval for a new dosing schedule that significantly lowers ARIA-E risk while maintaining amyloid ...

Eli Lilly and Company (NYSE:LLY) is one of the most frequently discussed stocks on Cramer’s morning show.